Dr. Rini on Sequencing of Immunotherapy Combinations in RCC

Brian I. Rini, MD,
Published: Thursday, Jul 20, 2017



Brian I. Rini, MD, professor of Medicine, Cleveland Clinic, discusses sequencing of immunotherapy combinations for patients with renal cell carcinoma (RCC).

According to Rini, not all of the combinations are going to be getting the same amount of use, causing competition between the combination regimens.

Sequencing of these agents is still a remaining question that needs further trials to investigate, explains Rini.

SELECTED
LANGUAGE


Brian I. Rini, MD, professor of Medicine, Cleveland Clinic, discusses sequencing of immunotherapy combinations for patients with renal cell carcinoma (RCC).

According to Rini, not all of the combinations are going to be getting the same amount of use, causing competition between the combination regimens.

Sequencing of these agents is still a remaining question that needs further trials to investigate, explains Rini.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: New Directions in Advanced Cutaneous Squamous Cell Carcinoma: Emerging Evidence of ImmunotherapyAug 13, 20191.5
Publication Bottom Border
Border Publication
x